BARRON’S MAGAZINE: The latest issue features ‘The King Of ETFs’ – After a late start, Vanguard raced ahead with exchange-graded funds under CEO Salim Ramji. What’s next?

Vanguard Conquered the ETF World. Where It’s Aiming Next.

Here’s how CEO Salim Ramji plans to bring Vanguard’s low-cost, high-return formula to cash savings, financial advice, and active fixed income.

Uber Stock Looks Cheap. Here’s Why.

Its stock is down, but investors shouldn’t overreact to worries about the autonomous-vehicle business.

This Healthcare Services Stock Has 37% Upside

Medpace has carved out a niche helping smaller biotechs navigate the regulatory process.

The Hidden Red Flag in Wall Street’s Price Targets

Nvidia and other tech stocks have a wide “dispersion” of price targets. Why that could be a problem for investors.

BARRON’S MAGAZINE: The latest issue features Texas Economic Boom: How AI, Oil, and ‘Y’all Street’ Are Fueling Historic Growth

The New Wild West: Texas Experiments With Raw Capitalism

The state’s light regulation and low taxes are luring dozens of big companies. It’s also setting up a water crisis and a “race to the bottom” in shareholder protections.

SPACs Are Roaring Back. This Red-Hot Stock Is a Cautionary Tale.

Dave lost 97% of its value before a 1-for-32 reverse split. Now the fintech stock has surged back. The story is a warning to investors as SPACs mount a comeback.

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

Texas Bets Big on Stock Exchanges

Texas is taking steps toward becoming a rival financial center to New York. It won’t be so easy.

SpaceX Won’t Destroy Telecom—It Will Just Reinvent It

AT&T, Verizon, and T-Mobile shares fell after SpaceX announced plans to launch a mobile offering next year. The drop isn’t warranted.

BARRON’S MAGAZINE: The latest issue features…GLP-1s aren’t just for obesity anymore, and sales are exploding. Sizing up the winners.

Here Comes the Next Wave of GLP-1s. They’ll Treat a Lot More Than Obesity.

This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?

Nasdaq Records Worst July Since 2006

Despite Friday’s gains, the index wasn’t able to finish the month higher.

Treasuries Get Whacked by Japan’s Big Yen Fix

• Why 3 Fed Officials Voted for Rate Hikes 
• Op-Ed: A Federal Reserve Stuck in Limbo

---

Warsh Weighs Fewer Fed Meetings, Report Says

---

Nvidia Is the World’s Most Valuable Company Again

SpaceX Stock Just Hit a Record Low

• Roblox’s Worst Day Ever After Earnings